Related Experiment Videos
[A double-blind comparative study of intracoronary administration of GE-0943 and urokinase: multicenter study]
Insights
GE-0943, a plasminogen proactivator, effectively recanalized coronary arteries in acute myocardial infarction patients. The 6000-unit dose showed high efficacy and safety, outperforming urokinase.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Acute myocardial infarction (AMI) remains a leading cause of mortality.
- Effective reperfusion therapy is crucial for improving outcomes in AMI patients.
- Coronary thrombolysis aims to restore blood flow by dissolving thrombi.
Purpose of the Study:
- To evaluate the efficacy and safety of intracoronary GE-0943 compared to urokinase for coronary thrombolysis in AMI.
- To determine the optimal dosage of GE-0943 for recanalization.
Main Methods:
- A comparative study involving patients with acute myocardial infarction.
- Intracoronary administration of GE-0943 at doses of 6000 units and 3000 units.
- Comparison with intracoronary urokinase administration.
- Assessment of infarct-related artery recanalization rates and hemorrhagic complications.
Main Results:
- GE-0943 at 6000 units achieved a 92.0% recanalization rate, significantly higher than 3000 units (68.2%) and urokinase (70.4%).
- The 6000-unit GE-0943 group experienced no hemorrhagic complications.
- The 3000-unit GE-0943 group had one hemorrhagic complication, while the urokinase group had five.
Conclusions:
- Intracoronary GE-0943 is a highly effective thrombolytic agent for acute myocardial infarction.
- GE-0943 demonstrates a favorable safety profile, particularly at the 6000-unit dose, with minimal hemorrhagic complications.
- GE-0943 represents a promising therapeutic option for coronary thrombolysis.
Abstract:
Coronary thrombolysis with plasminogen proactivator, GE-0943, was undertaken in patients with acute myocardial infarction and compared with urokinase. Fifty patients were given 6000 units of GE-0943 intracoronary and the totally occluded infarct-related arteries were recanalized in 92.0%. Fifty-four patients who were given 3000 units of GE-0943 intracoronary demonstrated a recanalization rate of 68.2%, while intracoronary administration of urokinase in 54 patients showed a recanalization rate of 70.4%. There was only one patient with hemorrhagic complication among GE-0943 3000-units group, none among GE-0943 6000-units group, and 5 among urokinase group. Thus, intracoronary administration of GE-0943 is very effective and safe with a dose up to 6000 units.